Up to 45 percent of SARS-CoV-2 infections may be asymptomatic
- Details
- Category: Research
An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a Scripps Research analysis of public datasets on asymptomatic infections.
The findings, published in Annals of Internal Medicine, suggest that asymptomatic infections may account for as much as 45 percent of all COVID-19 cases,
Promising path found for COVID-19 therapeutics
- Details
- Category: Research
A team of researchers at the University of Georgia has successfully demonstrated that a set of drug-like small molecules can block the activity of a key SARS-CoV-2 protein - providing a promising path for new COVID-19 therapeutics.
Led by Scott Pegan, director of UGA's Center for Drug Discovery, the team was the first to evaluate the SARS-CoV-2 protein PLpro, known to be essential in
A protein that helps to fight viruses can also block lung damage repair
- Details
- Category: Research
Researchers at the Francis Crick Institute have found that a protein which is initially helpful in the body's immune response to a virus, can later interfere with the repair of lung tissue. The work, published in Science, highlights the need for careful consideration regarding the use of this protein to treat viruses, including coronavirus.
COVID-19 mouse model will speed search for drugs, vaccines
- Details
- Category: Research
The global effort to quickly develop drugs and vaccines for COVID-19 has been hampered by limited numbers of laboratory mice that are susceptible to infection with SARS-CoV-2, the virus that causes COVID-19. Now, researchers at Washington University School of Medicine in St. Louis report they have developed a mouse model of COVID-19 that replicates the illness in people.
Scientists identify targets for COVID-19 vaccine using cancer immunotherapy tools
- Details
- Category: Research
Cancer researchers at Children's Hospital of Philadelphia (CHOP) have harnessed tools used for the development of cancer immunotherapies and adapted them to identify regions of the SARS-CoV-2 virus to target with a vaccine, employing the same approach used to elicit an immune response against cancer cells to stimulate an immune response against the virus.
Study identifies potential approach to treat patients with severe COVID-19
- Details
- Category: Research
Early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein provided clinical benefit to a small group of patients with severe COVID-19. Researchers observed that the off-label use of the cancer drug acalabrutinib, a BTK inhibitor that is approved to treat several blood cancers, was associated with reduced respiratory distress and a reduction in the overactive immune response in most of the treated patients.
Scientists aim gene-targeting breakthrough against COVID-19
- Details
- Category: Research
A team of scientists from Stanford University is working with researchers at the Molecular Foundry, a nanoscience user facility located at the Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab), to develop a gene-targeting, antiviral agent against COVID-19.
More Pharma News ...
- First do no harm - researchers urge halt in prescribing hydroxycholoroquine for COVID-19
- Study finds COVID-19 convalescent plasma therapy safe, with 76% patients improving
- COVID-19 drug development could benefit from approach used against flu
- A roadmap for effective treatment of COVID-19
- Glucocorticoids are harmful in treating viral respiratory infections
- As businesses reopen, it's crucial we wear masks, safely distance
- Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery